Drug Profile
Research programme: septic shock therapy - Endotis
Alternative Names: EP XXLatest Information Update: 12 Aug 2009
Price :
$50
*
At a glance
- Originator Endotis Pharma
- Class Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Septic shock
Most Recent Events
- 12 Aug 2009 Discontinued - Preclinical for Septic shock in France (unspecified route)
- 13 Jul 2004 Preclinical trials in Septic shock in France (unspecified route)